Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery

Purpose — to analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the FemtoLASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition.
Patients and methods. The study included 25 patients (50 eyes) who underwent a keratorefractive surgery (Femto-LASIK) and were prescribed instillations of artificial tear drops HILOPARIN-COMOD®. To analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the Femto-LASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition: UCVA, BCVA, Schirmer’s II test, tear break-up time (Norn’s test), OCT pachymetry of the cornea and corneal flap. The treatment effectiveness was evaluated at 1 day, 1 week, 1 and 3 months after the surgery.
Results. As a result of the treatment, the following refractive data were obtained: UCVA increased from 0.09 ± 0.02 to 0.94 ± 0.07 on the first day after surgery and to 0.96 ± 0.04 and 0.99 ± 0.07 to 1 and 3 months of follow-up, BCVA respectively, from 0.97 ± 0.04 to 0.94 ± 0.07, 0.97 ± 0.07 and 0.99 ± 0.07 after surgery. A faster restoration of the cornea and corneal valve was revealed, as evidenced by a decrease in their thickness already in the 1st week after surgery in comparison with the control group, where were more pronounced changes occur only by the 1st and 3rd month of observation (p ≤ 0.05). There was a significant increase in the basal secretion of the lacrimal gland (Schirmer’s II test) from 10.16 ± 1.33 to 11.66 ± 1.13 and 12.88 ± 0.96 µm by 1 and 3 months after surgical treatment, respectively (p ≤ 0.05). The Norn’s test increased from 10.89 ± 1.94 to 12.78 ± 1.59 and 13.83 ± 0.5 s to 1 and 3 months of treatment, respectively (p ≤ 0.05).
Conclusion. The effectiveness of the HILOPARIN-COMOD® use in the correction of the dry eye syndrome after keratorefractive operations has been proven. The obtained results clearly demonstrate that the HILOPARIN-COMOD® preparation enhances not only the stability of the tear film, but also the restoration of the OCT morphometric parameters of the thickness of the cornea and corneal flap.

1. Toda I., Yagi Y., Hata S. Eximer laser photorefractive keratectomy for patients with contact lens intolerance caused by dry eye. Br. J. Ophtalmol. 1996;80(7):604–609. DOI: 10.1136/bjo.80.7.604

2. Quinto G.G., Camacho W., Behrens A. Postrefractive surgery dry eye. Current Opinion in Ophthalmology. 2008;19(4):335–341. DOI: 10.1097/ICU.0b013e3283009ef8

3. Albietz J.M., McLennan S.G., Lenton L.M. Ocular surface management of photorefractive keratectomy and laser in situ keratomileusis. J Refract Surg. 2003;19(6):636–644.

4. Бржеский В.В., Сомов Е.Е. Роговично-конъюнктивальный ксероз (диагностика, клиника, лечение). СПб.: Левша; 2003:120. [Brzheskij V.V., Somov E.E. Corneal-conjunctival xerosis (diagnostics, clinic, treatment). Saint Peterburg: Levsha; 2003:120 (In Russ.)].

5. Кански Дж.Дж. Клиническая офтальмология. M.: Логосфера; 2009:249–321. [Kanski J.J. Clinical ophthalmology. Moscow: Logosfera; 2009:249–321 (In Russ.)].

6. Лобанова О.С. Инновационный способ диагностики и мониторинга лечения болезни глазной поверхности в практике врача-офтальмолога. Современная оптометрия. 2010;2:18–21. [Lobanova O.S. Innovative method of diagnosis and monitoring of treatment of eye surface disease in the practice of an ophthalmologist. Modern optometry = Sovremennaya optometriya. 2010;2:18–21 (In Russ.)].

7. The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). The Ocular Surface. 2007;5(2):75–92. DOI: 10.1016/s1542-0124(12)70081-2

8. Сомов Е.Е. Синдромы слезной дисфункции (анатомо-физиологические основы, диагностика, клиника и лечение). СПб.: Человек; 2011:160. [Somov E.E. Syndromes of lacrimal dysfunction (anatomophysiological basis, diagnosis, clinic and treatment). Saint Peterburg: Chelovek; 2011:160 (In Russ.)].

9. Baudouin C. Un nouveau schéma pour mieux comprendre les maladies de la surface oculaire. Journal Français d’Ophtalmologie. 2007;30(3):239–246. DOI: 10.1016/s0181-5512(07)89584-2

10. Pan Z., Wang Z., Yang H., Zhang F., Reinach P.S. TRPV1 Activation Is Required for Hypertonicity-Stimulated Inflammatory Cytokine Release in Human Corneal Epithelial Cells. Investigative Opthalmology & Visual Science. 2011;52(1):485–493. DOI: 10.1167/iovs.10-5801

11. Bozac E., Brief G., Margesco F., Munteanu H. Heparin in thetreatment of ocular burns caused by bases. Ann Ocul (Paris). 1967;200(6):693–700.

12. Оганезова Ж.Г. Препараты на основе гиалуроновой кислоты в лечении синдрома «сухого глаза». РМЖ. Клиническая офтальмология. 2013;3:119. [Oganezova Zh. G. Hyaluronic acid drugs in the treatment of dry eye syndrome. Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2013;3:119 (In Russ.)].

13. Mencucci R., Boccalini C., Caputo R. Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film in stability after cataract surgery. J Cataract Refract Surg. 2015 Aug;41(8):1699–1704. DOI: 10.1016/j.jcrs.2014.12.056

14. Ткаченко Н.В., Астахов С.Ю. Опыт применения «Хилопарина» в клинической практике. Офтальмологические ведомости. 2014;7(4):53–62. [Tkachenko N.V., Astakhov S.Yu. The experience of “Hyloparin” use in clinical practice. Ophthalmology journal = Oftal’mologicheskie vedomosti. 2014;7(4):53–62 (In Russ.)]. DOI: 10.17816/OV2014453-62

15. Чернакова Г.М., Майчук Д.Ю., Слонимский Ю.Б., Слонимский А.Ю., Клещева Е.А., Мезенцева М.В. Новые свойства слезозаместителя, содержащего гепарин, в условиях in vitro (потенциальный противовирусный и противовоспалительный эффект). Офтальмология. 2018;15(2):182–188. [Chernakova G.M., Maychuk D.Yu., Slonimsky Yu.B., Slonimskiy A.Yu., Kleshcheva E.A., Mezentseva M.V. New Properties of the Heparin-Containing Drug in vitro (Potential Antiviral and Anti-Inflammatory Effects). Оphthalmology in Russia = Oftal’mologi ya.2018;15(2):182–188 (In Russ.)]. DOI: 10.18008/1816-5095-2018-2-182-188

16. Чернакова Г.М., Майчук Д.Ю., Клещева Е.А., Лошкарева А.О., Семенова Т.Б. Рекомендации по ведению пациентов с герпетическим кератитом/ кератоувеитом затяжного течения: от проблем к решению. Офтальмология. 2019;16(4):537–545. [Chernakova G.M., Maychuk D.Y., Kleshcheva E.A., Loshkareva A.O., Semenova T.B. Guidelines for the Management of Patients with Herpetic Keratitis/Keratouveitis in the Long Term: from Problem to Solution. Оphthalmology in Russia = Oftal’mologiya.2019;16(4):537–545 (In Russ.)]. DOI: 10.18008/1816-5095-2019-4-537-545

17. Eгоров Е.А., Романова Т.Б., Кац Д.В. Применение раствора Хилопарин-КОМОД® в офтальмологической практике (пилотное исследование). РМЖ. Клиническая офтальмология. 2014;4:207–212. [Egorov E.A., Romanova T.B., Katz D.V. Application of the solution Hylo-parin-COMOD® in ophthalmological practice (pilot study). Russian Medical Journal. Clinical Ophthalmology = Rossijskij medicinskij zhurnal. Klinicheskaya oftal’mologiya. 2014;4:207–212 (In Russ.)].